Amgen Inc.

Marissa Mock

Gunasekaran Kannan

Zhulun Wang

Ian Nevin Foltz

Xiaoshan Min

Kenneth William Walker

Agnes Eva Hamburger

Jackie Zeqi Sheng

Neeraj Jagdish Agrawal

Yi Lin Zhang

Murielle M Veniant-Ellison

YuMei Xiong

Jie Tang

Grant Shimamoto

Khaled M K Z Ali

Shunsuke Takenaka

Darren L Bates

Kathy Manchulenko

Yannick Bulliard

Yi Zhang

Agnieszka Kielczewska

Sue J Sohn

Daren Bates

Yumei Xiong

Ian Foltz

Shunseke Takenaka

Khaled MKZ Ali

Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.

TIGIT and CD112R blockade

Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.

Interleukin-21 mutein/ anti-PD-1 antibody conjugates

Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.

Anti-PD-1 antibodies and methods of treatment

Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) constructs

Growing community of inventors

Newbury Park, CA, United States of America

Marissa Mock